MarketPulse
P

$PHAR

5 articles found
3 positive
1 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pharming Charts Growth Despite RUCONEST Decline, Bets on Joenja Expansion

Pharming Group's Q1 2026 revenues fell 8% YoY to $72.4M, hurt by RUCONEST decline, but Joenja surged 34%. Company maintains full-year guidance and advances international launches.
PHAR2026 guidancecash flow positive
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pharming Group to Unveil Q1 2026 Results, AGM Set for Late May

Pharming Group will report Q1 2026 results May 7 with conference call; 2026 Annual General Meeting scheduled for May 28.
PHARfinancial resultsconference call
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pharming Group Boosts Investor Outreach Amid Leniolisib CHMP Approval Win

Pharming Group schedules April 2026 investor conferences following positive CHMP opinion for Joenja® leniolisib in APDS treatment.
PHARinvestor conferencebiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Pharming Group N.V.

Pharming Wins Japan Approval for Joenja, First APDS Treatment for Young Children

Pharming secures Japan approval for Joenja, first APDS treatment for children aged 4-11 globally, based on positive Phase III data showing lymphadenopathy reduction and immune function improvement.
PHARpediatric treatmentorphan drug
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Initiates Securities Investigation into Pharming Group Following FDA Rejection

Pomerantz Law Firm investigates Pharming Group after FDA rejects pediatric drug application, causing 17% stock decline. Inquiry focuses on whether regulatory risks were adequately disclosed to investors.
PHARsecurities fraudclass action lawsuit